<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00298233</url>
  </required_header>
  <id_info>
    <org_study_id>SEA 001</org_study_id>
    <secondary_id>N01A050042</secondary_id>
    <nct_id>NCT00298233</nct_id>
  </id_info>
  <brief_title>High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza</brief_title>
  <official_title>High-Dose Versus Standard-Dose Oseltamivir for the Treatment of Severe Influenza and Avian Influenza: A Phase II Double-Blind, Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Influenza, also known as the flu, is a contagious respiratory illness caused by influenza
      viruses. The illness can range in severity, from mild to severe to even death, and it causes
      an estimated 500,000 to 1,000,000 deaths worldwide each year. In the last several years,
      there have been increasing numbers of human cases of avian influenza, or bird flu. This trend
      may pose a threat of a future pandemic--worldwide outbreak of disease--with an avian
      influenza virus that can easily spread from person to person. Oseltamivir is an antiviral
      medication that is used to treat people with uncomplicated human influenza, and it may be
      effective in treating people with either severe human influenza or avian influenza. The
      purpose of this international study is to compare standard-dose oseltamivir versus high-dose
      oseltamivir for treating people who are hospitalized with severe human influenza or avian
      influenza.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two main types of influenza virus--Types A and B--are responsible for the seasonal flu
      epidemics that occur each year. The influenza A viruses can be broken down into subtypes
      based on two proteins on the surface of the virus: hemagglutinin (H) and neuraminidase (N).
      The A subtypes usually found in humans are H1N1, H1N2, and H3N2. Other A subtypes are found
      primarily in animals. For example, the &quot;avian influenza virus&quot; refers to an influenza A virus
      that is found chiefly in birds.

      Although avian influenza does not usually affect humans, increasing numbers of cases of human
      infection from avian influenza virus H5N1 have been reported in the last several years.
      Because all influenza viruses have the ability to modify, there is concern that this trend of
      increasing cases may pose a threat of a future pandemic with a new H5N1 virus that could
      spread easily from person to person.

      The H5N1 virus that has caused human infection in Asia is resistant to amantadine and
      rimantadine, two antiviral medications commonly used for treating people with influenza.
      Another antiviral medication, oseltamivir, is currently used to treat people with
      uncomplicated human influenza. The purpose of this study is to compare standard-dose
      oseltamivir and high-does oseltamivir for treating people who are hospitalized with severe
      human influenza or avian influenza. The study will also attempt to identify how severe human
      influenza and avian influenza differ in the following factors: clinical manifestation,
      relationship between antiviral plasma concentrations and viral dynamics, and pathogenesis.

      Upon meeting certain screening criteria, participants will be randomly assigned to receive
      oseltamivir either at a standard-dose level (75 mg twice daily orally or equivalent dose
      adjusted for age, weight, and kidney function) or at a high-dose level (150 mg twice daily
      orally or equivalent dose adjusted for age, weight, and kidney function). Treatment will
      continue for 5 days, after which participants who meet clinical failure criteria will
      continue their assigned treatment for an additional 5 days. It is anticipated that
      participants will remain hospitalized through the course of treatment. On Day 0, which marks
      the first day of hospitalization, participants will undergo a medical review, physical
      examination, blood sampling, nasal swab, throat swab, anal swab, and chest x-ray. An
      endotracheal aspirate procedure and urine sampling may also be performed. During the hospital
      stay, most of the above procedures will be repeated regularly, and additional samples of lung
      fluid, cerebral spinal fluid, and pleural fluid may be obtained. On Day 5 and possibly on Day
      10, participants will undergo a follow-up x-ray. If applicable, participants will attend
      outpatient study visits on Days 10, 14, and 28 for further evaluation; participants with
      avian influenza will also attend visits on Days 56 and 180.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of All Participants Negative for Viral RNA on Day 5</measure>
    <time_frame>After 5 days of treatment</time_frame>
    <description>Proportion of all participants with no detectable viral RNA by reverse transcriptase-polymerase chain reaction (RT-PCR) in a combined nasal and throat swab sample on day 5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants Meeting Criteria for Day 5 Clinical Failure</measure>
    <time_frame>After 5 days of treatment</time_frame>
    <description>Proportion of participants that have clinical failure by day 5. Subjects that meet one of the following on Day 5 will be classified as a clinical failure:
Severe tachypnea (respiratory rate ≥ 30 for ages ≥12 years, rate ≥ 40 for ages 6 to 12 years, rate ≥45 for ages 3 to 6 years, rate ≥ 50 for ages 1 to 3 years)
Severe dyspnea (unable to speak full sentences, or use of accessory respiratory muscles)
Arterial oxygen saturation ≤92% on room air by trans-cutaneous method
Need for mechanical ventilation or intensive care unit (ICU) admission For the purpose of endpoint definition, death prior to or on Day 5 will also be considered a clinical failure at Day 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital Mortality Rates</measure>
    <time_frame>After up to 10 days of treatment</time_frame>
    <description>Standard therapy with oseltamivir is five days. Those patients with persistent symptoms on day five were continued on the randomized dose for an additional five days and assessments were performed up to day 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time (Days) Receipt of Oxygen</measure>
    <time_frame>Throughout study, 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time (Days) in ICU</measure>
    <time_frame>Throughout study, 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time (Days) on Ventilation</measure>
    <time_frame>Throughout study, 14 days</time_frame>
    <description>Use of mechanical ventilation at any time for subjects with severe influenza and avian influenza.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">326</enrollment>
  <condition>Influenza</condition>
  <condition>Avian Influenza</condition>
  <condition>Severe Influenza</condition>
  <arm_group>
    <arm_group_label>Standard Dose oseltamivir adult cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All participants &gt;= 15 years will receive standard-dose oseltamivir (75 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double Dose oseltamivir Adult cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All participants &gt;= 15 years will receive high-dose oseltamivir (150 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Dose Oseltamivir child cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All participants &lt;15 years will receive standard-dose oseltamivir (75 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double Dose Oseltamivir child cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All Participants &lt;15 years will receive high-dose oseltamivir (150 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir</intervention_name>
    <description>Oseltamivir is a sialic acid analogue that potently and specifically inhibits the viral neuraminidases by competitively and reversibly interacting with the active enzyme site of influenza A and B viruses. Oseltamivir will be administered orally in standard formulations (capsules for adults and children at least 15 years of age; suspension for children younger than 15 years).</description>
    <arm_group_label>Standard Dose oseltamivir adult cohort</arm_group_label>
    <arm_group_label>Double Dose oseltamivir Adult cohort</arm_group_label>
    <arm_group_label>Standard Dose Oseltamivir child cohort</arm_group_label>
    <arm_group_label>Double Dose Oseltamivir child cohort</arm_group_label>
    <other_name>Tamiflu</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least one of the following respiratory symptoms: cough, dyspnea, sore throat

          -  Evidence of severe influenza or avian influenza, as defined below

          -  Severe influenza infection criteria:

               1. Need for hospitalization

               2. One of the following:

                    1. New infiltrate on chest x-ray (or any infiltrate if no prior chest x-ray or
                       not known)

                    2. Severe tachypnea (more information on this criterion can be found in the
                       protocol)

                    3. Severe dyspnea

                    4. Arterial oxygen saturation of 92% or less on room air by trans-cutaneous
                       method

               3. Positive diagnostic testing for influenza, as defined by either rapid influenza
                  antigen (Ag) positive (A or B) or qualitative reverse transcriptase-polymerase
                  chain reaction (RT-PCR) positive for any influenza

               4. Illness (defined by onset of fever, respiratory symptoms, or constitutional
                  symptoms) began within 10 days before study enrollment

          -  Avian influenza infection criteria:

               1. Nasal wash, nasopharyngeal aspirate, endotracheal aspirate, nasal swab, or throat
                  swab that is RT-PCR positive influenza for H5 influenza

               2. Illness (defined by onset of fever, respiratory symptoms, or constitutional
                  symptoms) began within 14 days before study enrollment

        Exclusion Criteria:

          -  Received more than 72 hours of oseltamivir (six doses) within 14 days

          -  Received oseltamivir at higher than standard doses within the last 14 days or during
             current acute illness, whichever is longer

          -  History of allergy or severe intolerance of oseltamivir, as determined by the
             investigator

          -  Alternate explanation for the clinical findings, as determined by the investigator and
             with the information immediately available

          -  Creatine clearance less than 10 ml/minute

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tawee Chotpitayasunohdh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Sirikit National Institute of Child Health, Bangkok, Thailand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tran Tinh Hien, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital, National University of Singapore</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Sirikit National Institute of Child Health</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bamrasnaradura Infectious Disease Institute</name>
      <address>
        <city>Nonthaburi</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chest Disease Institute</name>
      <address>
        <city>Nonthaburi</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital of Pediatrics</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute fof Infectious and Tropical Diseases</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital #1</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Tropical Diseases</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Hospital #2</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
    <country>Thailand</country>
    <country>Vietnam</country>
  </location_countries>
  <removed_countries>
    <country>Indonesia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.seaicrn.org</url>
    <description>South East Asian Infectious Diseases Clinical Research Network - Protocol and support documents available</description>
  </link>
  <reference>
    <citation>Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis. 1995 Jan-Mar;1(1):7-15. Review.</citation>
    <PMID>8903148</PMID>
  </reference>
  <reference>
    <citation>Colman PM. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci. 1994 Oct;3(10):1687-96. Review.</citation>
    <PMID>7849585</PMID>
  </reference>
  <reference>
    <citation>de Jong MD, Bach VC, Phan TQ, Vo MH, Tran TT, Nguyen BH, Beld M, Le TP, Truong HK, Nguyen VV, Tran TH, Do QH, Farrar J. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med. 2005 Feb 17;352(7):686-91.</citation>
    <PMID>15716562</PMID>
  </reference>
  <results_reference>
    <citation>South East Asia Infectious Disease Clinical Research Network. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ. 2013 May 30;346:f3039. doi: 10.1136/bmj.f3039.</citation>
    <PMID>23723457</PMID>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2006</study_first_submitted>
  <study_first_submitted_qc>February 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2006</study_first_posted>
  <results_first_submitted>January 17, 2014</results_first_submitted>
  <results_first_submitted_qc>April 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 22, 2014</results_first_posted>
  <last_update_submitted>May 26, 2014</last_update_submitted>
  <last_update_submitted_qc>May 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oxford University Clinical Research Unit, Vietnam</investigator_affiliation>
    <investigator_full_name>Jeremy Farrar</investigator_full_name>
    <investigator_title>Director, Oxford University Clinical Research Unit</investigator_title>
  </responsible_party>
  <keyword>Antibody Response</keyword>
  <keyword>Antiviral Efficacy</keyword>
  <keyword>Bird Flu</keyword>
  <keyword>Severe Respiratory Distress</keyword>
  <keyword>Viral Replication and Shedding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Dose Oseltamivir Adult Cohort</title>
          <description>All participants &gt;= 15 years received standard-dose oseltamivir (75 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.</description>
        </group>
        <group group_id="P2">
          <title>Double Dose Oseltamivir Adult Cohort</title>
          <description>All Participants &gt;= 15 years received high-dose oseltamivir (150 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.</description>
        </group>
        <group group_id="P3">
          <title>Standard Dose Oseltamivir Child Cohort</title>
          <description>All participants &lt;15 years received standard dose oseltamivir (75 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.</description>
        </group>
        <group group_id="P4">
          <title>Double Dose Oseltamivir Child Cohort</title>
          <description>All Participants &lt;15 years received high-dose oseltamivir (150 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="122"/>
                <participants group_id="P4" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="122"/>
                <participants group_id="P4" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants that were randomized</population>
      <group_list>
        <group group_id="B1">
          <title>Standarad Dose Oseltamivir</title>
          <description>All participants that were randomized and received standard dose oseltamivir</description>
        </group>
        <group group_id="B2">
          <title>Double Dose Oseltamivir</title>
          <description>All participants that were randomized and received doubledose oseltamivir</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="161"/>
            <count group_id="B2" value="165"/>
            <count group_id="B3" value="326"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Child cohort: ≥1 to &lt;15 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adult cohort: ≥15 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of All Participants Negative for Viral RNA on Day 5</title>
        <description>Proportion of all participants with no detectable viral RNA by reverse transcriptase-polymerase chain reaction (RT-PCR) in a combined nasal and throat swab sample on day 5.</description>
        <time_frame>After 5 days of treatment</time_frame>
        <population>All randomized patients with RT-PCR proven influenza.</population>
        <group_list>
          <group group_id="O1">
            <title>Double Dose Oseltamivir</title>
            <description>All participants receiving double dose oseltamivir</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Oseltamivir</title>
            <description>All participants receiving standard dose oseltamivir</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of All Participants Negative for Viral RNA on Day 5</title>
          <description>Proportion of all participants with no detectable viral RNA by reverse transcriptase-polymerase chain reaction (RT-PCR) in a combined nasal and throat swab sample on day 5.</description>
          <population>All randomized patients with RT-PCR proven influenza.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Based on previous studies, assumption was made that 30% of children and 55% of adults treated with standard dose oseltamivir would test negative for virus on day five. This would require a sample size of 242 patients to show a 20% absolute improvement in cessation of viral shedding with 85% power and a two sided α of 0.05. To allow for study withdrawals, the target sample size was set at 300 patients.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.42</p_value>
            <p_value_desc>Significance assessed at the 5% level for a two-sided comparison</p_value_desc>
            <method>conditional univariate logistic regressi</method>
            <method_desc>analysis stratified by study site</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Meeting Criteria for Day 5 Clinical Failure</title>
        <description>Proportion of participants that have clinical failure by day 5. Subjects that meet one of the following on Day 5 will be classified as a clinical failure:
Severe tachypnea (respiratory rate ≥ 30 for ages ≥12 years, rate ≥ 40 for ages 6 to 12 years, rate ≥45 for ages 3 to 6 years, rate ≥ 50 for ages 1 to 3 years)
Severe dyspnea (unable to speak full sentences, or use of accessory respiratory muscles)
Arterial oxygen saturation ≤92% on room air by trans-cutaneous method
Need for mechanical ventilation or intensive care unit (ICU) admission For the purpose of endpoint definition, death prior to or on Day 5 will also be considered a clinical failure at Day 5.</description>
        <time_frame>After 5 days of treatment</time_frame>
        <population>For the purpose of endpoint definition, death prior to or on Day 5 was also considered as clinical failure on day 5.In the double dose cohort, only 154 subjects completed fives days of drug and 7 died (total 161). In the standard dose cohort only 149 subjects completed 5 days of drug and 9 died (total 158).</population>
        <group_list>
          <group group_id="O1">
            <title>Double Dose Oseltamivir</title>
            <description>All participants receiving double dose oseltamivir</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Oseltamivir</title>
            <description>All participants receiving standard dose oseltamivir</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Meeting Criteria for Day 5 Clinical Failure</title>
          <description>Proportion of participants that have clinical failure by day 5. Subjects that meet one of the following on Day 5 will be classified as a clinical failure:
Severe tachypnea (respiratory rate ≥ 30 for ages ≥12 years, rate ≥ 40 for ages 6 to 12 years, rate ≥45 for ages 3 to 6 years, rate ≥ 50 for ages 1 to 3 years)
Severe dyspnea (unable to speak full sentences, or use of accessory respiratory muscles)
Arterial oxygen saturation ≤92% on room air by trans-cutaneous method
Need for mechanical ventilation or intensive care unit (ICU) admission For the purpose of endpoint definition, death prior to or on Day 5 will also be considered a clinical failure at Day 5.</description>
          <population>For the purpose of endpoint definition, death prior to or on Day 5 was also considered as clinical failure on day 5.In the double dose cohort, only 154 subjects completed fives days of drug and 7 died (total 161). In the standard dose cohort only 149 subjects completed 5 days of drug and 9 died (total 158).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.54</p_value>
            <p_value_desc>Significance assessed at the 5% level for a two-sided comparison</p_value_desc>
            <method>Mantel Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-hospital Mortality Rates</title>
        <description>Standard therapy with oseltamivir is five days. Those patients with persistent symptoms on day five were continued on the randomized dose for an additional five days and assessments were performed up to day 10.</description>
        <time_frame>After up to 10 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Double Dose Oseltamivir</title>
            <description>All participants receiving double dose oseltamivir</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Oseltamivir</title>
            <description>All participants receiving standard dose oseltamivir</description>
          </group>
        </group_list>
        <measure>
          <title>In-hospital Mortality Rates</title>
          <description>Standard therapy with oseltamivir is five days. Those patients with persistent symptoms on day five were continued on the randomized dose for an additional five days and assessments were performed up to day 10.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.54</p_value>
            <p_value_desc>Significance assessed at the 5% level for a two-sided comparison</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel chi-square stratified by study site</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time (Days) Receipt of Oxygen</title>
        <time_frame>Throughout study, 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Double Dose Oseltamivir</title>
            <description>All participants receiving double dose oseltamivir</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Oseltamivir</title>
            <description>All participants receiving standard dose oseltamivir</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time (Days) Receipt of Oxygen</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="2-5" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="3.5" spread="2-7" lower_limit="2" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <p_value_desc>Significance assessed at the 5% level for a two-sided comparison</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time (Days) in ICU</title>
        <time_frame>Throughout study, 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Double Dose Oseltamivir</title>
            <description>All participants receiving double dose oseltamivir</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Oseltamivir</title>
            <description>All participants receiving standard dose oseltamivir</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time (Days) in ICU</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O2" value="5" lower_limit="2" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.66</p_value>
            <p_value_desc>Significance assessed at the 5% level for a two-sided comparison</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time (Days) on Ventilation</title>
        <description>Use of mechanical ventilation at any time for subjects with severe influenza and avian influenza.</description>
        <time_frame>Throughout study, 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Double Dose Oseltamivir</title>
            <description>All participants receiving double dose oseltamivir</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Oseltamivir</title>
            <description>All participants receiving standard dose oseltamivir</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time (Days) on Ventilation</title>
          <description>Use of mechanical ventilation at any time for subjects with severe influenza and avian influenza.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1" upper_limit="16"/>
                    <measurement group_id="O2" value="5" lower_limit="2" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.58</p_value>
            <p_value_desc>Significance assessed at the 5% level for a two-sided comparison</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through Day 28 for severe influenza, and Day 180 for avian influenza.</time_frame>
      <desc>The study recorded only cumulative data (total number of AEs per type, per Arm, but not number of subjects affected per AE type). Therefore data are the number of events and not the number of participants with events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Double Dose Oseltamivir</title>
          <description>The study recorded only cumulative data (total number of adverse events (AEs) per type, per Arm, but not number of subjects affected per AE type). Therefore data are the number of events and not the number of participants with events.</description>
        </group>
        <group group_id="E2">
          <title>Standard Dose Oseltamivir</title>
          <description>The study recorded only cumulative data (total number of adverse events (AEs) per type, per Arm, but not number of subjects affected per AE type). Therefore data are the number of events and not the number of participants with events.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>WHO ATC</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Septic shock</sub_title>
                <description>A participant was admitted to the hospital for suspected pneumonia. Following upper GI bleeding and respiratory failure, diagnosis confirmed as septic shock. Subject eventually stabilized. Unblinding revealed subject was on high dose oseltamivir.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>WHO ATC</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>multi-organ failures</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>other</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>respiratory failure</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jeremy Farrar</name_or_title>
      <organization>Oxford University Clinical Research Unit</organization>
      <phone>+84 839237954</phone>
      <email>info@oucru.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

